Pharmaceutical-Induced Dyskinesia: A Case Study of Thoracotomy Treated with Amantadine
Abstract
Dyskinesia, marked by involuntary and irregular movements, can result from various pharmaceutical agents. The case presented features a patient undergoing thoracotomy, experiencing dyskinesia, likely attributed to antipsychotics, antiemetics, and antibiotics, and subsequently treated with amantadine.
[1] Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005;252(10):1299-306. https://doi.org/10.1007/s00415-005-0006-x
[2] Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18(1):15-20. https://doi.org/10.1017/S1092852912000752
[3] Miller LG, Jankovic J. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med. 1989;149(11):2486-92. https://doi.org/10.1001/archinte.1989.00390110070015
[4] Tianyi F-L, Agbor VN, Njim T. Metoclopramide induced acute dystonic reaction: a case report. BMC Res Notes. 2017;10:1-3. https://doi.org/10.1186/s13104-016-2342-6
[5] Campbell D. The management of acute dystonic reactions. Aust Prescr. 2001;24(1):19-20. https://doi.org/10.18773/
austprescr.2001.011
[6] Karagoz G, Kadanali A, Dede B, Anadol U, Yucel M, Bektasoglu MF. Metoclopramide-induced acute dystonic reaction: a case report. Eurasian J Med. 2013;45(1):58-60. https://doi.org/10.5152/eajm.2013.10
[7] Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry.1987;22(8):1004-20. https://doi.org/10.1016/0006-3223(87) 90010-2
[8] Caroff SN, Mann SC, Sullivan KA, Campbell EC. Neuroleptic malignant syndrome. In: Movement Disorder Emergencies: Diagnosis and Treatment. 2022:95-113. https://doi.org/10.1007/978-3-030-75898-1_6
[9] Plant G. Focal paroxysmal kinesigenic choreoathetosis. J Neurol Neurosurg Psychiatry. 1983;46(4):345-8. https://doi.
org/10.1136/jnnp.46.4.345
[10] Delay J. Un neuroleptique majeur non phenothiazinique et non réserpinique, l’halopéridol, dans le traitement des psychoses. Ann Med Psychol (Paris). 1960;118(1):145-52.
[11] Rupniak N, Jenner P, Marsden C. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl). 1986;88(4):403- 19. https://doi.org/10.1007/BF00178501
[12] Host BD, Sloan W. Orofacial dyskinesia associated with the use of levofloxacin. Ann Pharmacother. 2014;48(1):142-4. https://doi.org/10.1177/1060028013507050
[13] Lee CH, Cheung RT, Chan TM. Ciprofloxacin-induced oral facial dyskinesia in a patient with normal liver and renal function. Hosp Med. 2000;61(2):142-3. https://doi.org/10.12968/hosp.2000.61.2.2404
[14] Manabe S, Yanagi H, Ozawa H, Takagi A. Case Report: Neuroleptic malignant syndrome as part of an akinetic crisis
associated with sepsis in a patient with Lewy body disease. BMJ Case Rep. 2019;12(2):e227722 . https://doi.org/10.1136/bcr-2018-227216
[15] Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L. Drug-induced movement disorders. Expert Opin Drug Saf. 2015;14(6):877-90. https://doi.org/10.1517/14740338.2015.1032244
[16] Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions.
J Clin Psychopharmacol. 1987;7(3):164-6. https://doi. org/10.1097/00004714-198706000-00008
[17] Moleman P, Schmitz PJ, Ladee GA. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics. J Clin Psychiatry. 1982;43(12):492-6.
[18] Chiles JA. Extrapyramidal reactions in adolescents treated with high-potency antipsychotics. Am J Psychiatry. 1978;135(2):239- 40. https://doi.org/10.1176/ajp.135.2.239
[19] Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40(10):1113-7. https://doi. org/10.1001/archpsyc.1983.01790090075012
[20] Livezey MR, Briggs ED, Bolles AK, Nagy LD, Fujiwara R, Furge LL. Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica.2014;44(4):309-19. https://doi.org/10.3109/00498254.2013.8 35885
[21] Bateman D, Rawlins M, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ. 1985;291(6500):930-2. https://doi.org/10.1136/bmj.291.6500.930
[22] Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna). 2018;125(8):1237-50. https://doi.org/10.1007/s00702-018-1869-1
[2] Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18(1):15-20. https://doi.org/10.1017/S1092852912000752
[3] Miller LG, Jankovic J. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med. 1989;149(11):2486-92. https://doi.org/10.1001/archinte.1989.00390110070015
[4] Tianyi F-L, Agbor VN, Njim T. Metoclopramide induced acute dystonic reaction: a case report. BMC Res Notes. 2017;10:1-3. https://doi.org/10.1186/s13104-016-2342-6
[5] Campbell D. The management of acute dystonic reactions. Aust Prescr. 2001;24(1):19-20. https://doi.org/10.18773/
austprescr.2001.011
[6] Karagoz G, Kadanali A, Dede B, Anadol U, Yucel M, Bektasoglu MF. Metoclopramide-induced acute dystonic reaction: a case report. Eurasian J Med. 2013;45(1):58-60. https://doi.org/10.5152/eajm.2013.10
[7] Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry.1987;22(8):1004-20. https://doi.org/10.1016/0006-3223(87) 90010-2
[8] Caroff SN, Mann SC, Sullivan KA, Campbell EC. Neuroleptic malignant syndrome. In: Movement Disorder Emergencies: Diagnosis and Treatment. 2022:95-113. https://doi.org/10.1007/978-3-030-75898-1_6
[9] Plant G. Focal paroxysmal kinesigenic choreoathetosis. J Neurol Neurosurg Psychiatry. 1983;46(4):345-8. https://doi.
org/10.1136/jnnp.46.4.345
[10] Delay J. Un neuroleptique majeur non phenothiazinique et non réserpinique, l’halopéridol, dans le traitement des psychoses. Ann Med Psychol (Paris). 1960;118(1):145-52.
[11] Rupniak N, Jenner P, Marsden C. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl). 1986;88(4):403- 19. https://doi.org/10.1007/BF00178501
[12] Host BD, Sloan W. Orofacial dyskinesia associated with the use of levofloxacin. Ann Pharmacother. 2014;48(1):142-4. https://doi.org/10.1177/1060028013507050
[13] Lee CH, Cheung RT, Chan TM. Ciprofloxacin-induced oral facial dyskinesia in a patient with normal liver and renal function. Hosp Med. 2000;61(2):142-3. https://doi.org/10.12968/hosp.2000.61.2.2404
[14] Manabe S, Yanagi H, Ozawa H, Takagi A. Case Report: Neuroleptic malignant syndrome as part of an akinetic crisis
associated with sepsis in a patient with Lewy body disease. BMJ Case Rep. 2019;12(2):e227722 . https://doi.org/10.1136/bcr-2018-227216
[15] Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L. Drug-induced movement disorders. Expert Opin Drug Saf. 2015;14(6):877-90. https://doi.org/10.1517/14740338.2015.1032244
[16] Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions.
J Clin Psychopharmacol. 1987;7(3):164-6. https://doi. org/10.1097/00004714-198706000-00008
[17] Moleman P, Schmitz PJ, Ladee GA. Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics. J Clin Psychiatry. 1982;43(12):492-6.
[18] Chiles JA. Extrapyramidal reactions in adolescents treated with high-potency antipsychotics. Am J Psychiatry. 1978;135(2):239- 40. https://doi.org/10.1176/ajp.135.2.239
[19] Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40(10):1113-7. https://doi. org/10.1001/archpsyc.1983.01790090075012
[20] Livezey MR, Briggs ED, Bolles AK, Nagy LD, Fujiwara R, Furge LL. Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica.2014;44(4):309-19. https://doi.org/10.3109/00498254.2013.8 35885
[21] Bateman D, Rawlins M, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ. 1985;291(6500):930-2. https://doi.org/10.1136/bmj.291.6500.930
[22] Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna). 2018;125(8):1237-50. https://doi.org/10.1007/s00702-018-1869-1
| Files | ||
| Issue | Vol 9 No 4 (2024): July-August | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/crcp.v9i4.17983 | |
| Keywords | ||
| Dyskinesia Amantadine Adverse effect Thoracotomy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Mojtahedzadeh M, Najafi A, Hosseinzadeh F, Saghafi F. Pharmaceutical-Induced Dyskinesia: A Case Study of Thoracotomy Treated with Amantadine. CRCP. 2025;9(4):169-172.
